Neurol. praxi. 2015;16(5):253-256

Neuropathic component of back pain

prof. MUDr. Josef Bednařík, CSc.
Neurologická klinika LF MU a FN, Brno

Back pain is probably the most prevalent clinical syndrome at all – lifetime prevalence is thought to be approximately >70% and currently about 30% of the population have this condition. Presently, chronic lumbar radicular pain is the most common neuropathic pain syndrome at all. Neuropathic component is present in at least 1/5 patients suffering from back pain. The pathophysiology of back pain is complex. Nociceptive – and neuropathic pain–generating mechanisms are thought to be involved, which established the term mixed pain syndrome. Radicular syndromes serve as typical examples of neuropathic pain. Neuropathic component, however, is also present in pseudoradicular and local types of back pain. Practical diagnostics of neuropathic back pain is based on the same diagnostic tools and principles as diagnosis of neuropathic pain in general. Current knowledge on the optimum therapy of neuropathic back pain is not sufficient to formulate unequivocal recommendations. Combined therapy utilising drugs focused to both nociceptive and neuropathic pain represents probably the best choice with respect to presumed pathophysiology of back pain in most patients.

Keywords: neuropathic pain, nociceptive pain, mixed pain, back pain

Published: October 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bednařík J. Neuropathic component of back pain. Neurol. praxi. 2015;16(5):253-256.
Download citation

References

  1. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on pharmacological treatment of neuropathic pain: 2009 revision. Eur J Neurol 2010; 17: 1113-1123. Go to original source... Go to PubMed...
  2. Attal N, Perrot S, Fermanian J, Bouhassira D. The neuropathic components of chronic low back pain: a prospective multicenter study using the DN4 questionnaire. J Pain 2011; 12: 1080-1087. Go to original source... Go to PubMed...
  3. Baron R, Freynhagen R, Tölle TR, Cloutier C, Leon T, Murphy TK, Phillips K; A0081007 Investigators. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 2010; 150(3): 420-427. Go to original source... Go to PubMed...
  4. Bednařík J, Ambler Z, Opavský J, Keller O, Rokyta R, Mazanec R, Lejčko J, Kozák J, Suchý M, Pátá M, Kožený P. Klinický standard pro farmakoterapii neuropatické bolesti. Cesk Slov Neurol N 2012; 75(108): 93-101.
  5. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004; 5: 143-149. Go to original source... Go to PubMed...
  6. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005; 114: 29-36. Go to original source... Go to PubMed...
  7. Freynhagen R, Baron R, Tölle T, Stemmler E, Gockel U, Stevens M, Maier C. Screening of neuropathic pain components in patients with chronic back pain associated with nerve root compression: a prospective observational pilot study (MIPORT). Curr Med Res Opin 2006; 22(3): 529-537. Go to original source... Go to PubMed...
  8. Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006; 22: 1911-1920. Go to original source... Go to PubMed...
  9. Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Current Pain & Headache Reports 2009; 13: 185-190. Go to original source... Go to PubMed...
  10. Freynhagen R, Rolke R, Baron R, Tölle TR, Rutjes AK, Schu S, Treede RD. Pseudoradicular and radicular low-back pain-a disease continuum rather than different entities? Answers from quantitative sensory testing. Pain 2008; 135: 65-74. Go to original source... Go to PubMed...
  11. Morlion B. Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. Curr Med Res Opin 2011; 27(1): 11-33. Go to original source... Go to PubMed...
  12. Pergolizzi JV Jr, Raffa RB, Taylor R Jr, Rodriguez G, Nalamachu S, Langley P. A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract 2013; 13(3): 239-252. Go to original source... Go to PubMed...
  13. Roman? CL, Roman? D, Lacerenza M. Antineuropathic and antinociceptive drugs combination in patients with chronic low back pain: a systematic review. Pain Res Treat 2012; 2012: 154781. Go to original source... Go to PubMed...
  14. Salda?a MT, Navarro A, Pérez C, Masramón X, Rejas J. Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings.heumatol Int 2010; 30(8): 1005-1015. Go to original source... Go to PubMed...
  15. Schmidt CO, Wenig CM, Schmidt U, Schmidt U, Gockel U, Freynhagen R, Tölle TR, Baron R, Kohlmann T. Modelling the prevalence and cost of back pain with neuropathic components in the general population. Eur J Pain 2009; 13(10): 1030-1035. Go to original source... Go to PubMed...
  16. Smart KM, Blake C, Staines A, Doody C. The Discriminative validity of "nociceptive," "peripheral neuropathic," and "central sensitization" as mechanisms-based classifications of musculoskeletal pain. Clin J Pain 2011; 27(8): 655-663. Go to original source... Go to PubMed...
  17. Steigerwald I, Müller M, Davies A, Samper D, Sabatowski R, Baron R, Rozenberg S, Szczepanska-Szerej A, Gatti A, Kress HG. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin 2012; 28(6): 911-936. Go to original source... Go to PubMed...
  18. Toelle TR, Varvara R, Nimour M, Emir B, Brasser M. Pregabalin in Neuropathic Pain Related to DPN, Cancer and Back Pain: Analysis of a 6-Week Observational Study. The Open Pain Journal 2012; 5: 1-11. Go to original source...
  19. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630-1635. Go to original source... Go to PubMed...
  20. Wenig CM, Schmidt CO, Kohlmann T, Schweikert B. Costs of back pain in Germany. Eur J Pain 2008; 13: 280-286. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.